<DOC>
	<DOCNO>NCT02045095</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 , dose escalation study expansion cohort evaluate safety ( establish MTD inform RP2D ) , tolerability , PK , pharmacodynamics , antitumor activity MLN7243 patient advance malignant solid tumor .</brief_summary>
	<brief_title>A Phase 1 , Dose Escalation Study MLN7243 Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : 1 . Male female patient 18 year old . 2 . Patients must histologically confirm diagnosis advance , metastatic malignant solid tumor must fail exhausted standard therapy standard therapy available . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Patients adequate hematologic organ function 5 . All patient must radiographically detectable tumor ; however , measurable disease define RECIST ( version 1.1 ) require participation dose escalation part study . 6 . Patients undergo biopsy procedure must accessible lesion safe biopsy . 7 . Recovered ( ie , ≤ Grade 1 toxicity ) reversible effect prior antineoplastic therapy , except alopecia . 8 . Female patient postmenopausal least 1 year screen visit , surgically sterile , agree practice 2 effective method contraception , time , time signing informed consent form 4 month last dose study drug , agree practice true abstinence . Male patient agree practice effective barrier contraception entire study treatment period 4 month last dose study drug agree practice true abstinence . 9 . Suitable venous access studyrequired blood sample include PK sampling . Exclusion Criteria Patients meeting follow exclusion criterion enrol study : 1 . Patients clinically significant preexist cardiac impairment . 2 . Patients know active CNS lesion exclude . Systemic antineoplastic therapy investigational agent within 21 day first dose study drug . 3 . Radiotherapy within 14 day first dose study drug allow except limited field radiotherapy palliative bone pain . 4 . For patient tumor biopsy require request : Any known coagulation abnormality would contraindicate tumor biopsy procedure . Ongoing therapy anticoagulant antiplatelet agent ( eg , aspirin , clopidogrel [ Plavix® ] , heparin , warfarin ) . 5 . Major surgery within 28 day first dose MLN7243 . 6 . Lifethreatening illness unrelated cancer . 7 . Any evidence active infection antibiotic therapy within 14 day first dose MLN7243 . 8 . Known human immunodeficiency virus ( HIV ) positivity AIDSrelated illness , hepatitis B virus , hepatitis C virus . 9 . Patients whose weight &lt; 40 kg . 10 . History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness , severe chronic obstructive pulmonary disease . 11 . Female patient lactate breastfeed positive serum pregnancy test Screening period positive urine pregnancy test Day 1 first dose study drug . For exhaustive list , please contact study central contact .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>